Image de couverture de livre

MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay

Beyond cure, major goals in patients with Hodgkin lymphoma (HL) are tailoring treatment to a patient’s individual risk for relapse to reduce acute and late toxicities, identifying candidates for early incorporation of novel agents, and making treatment affordable on a global level. Minimal residual...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Heger, Jan-Michel (Auteur) , Mattlener, Julia (Auteur) , Kaul, Helen (Auteur) , Ferdinandus, Justin (Auteur) , Schneider, Jessica (Auteur) , Schleifenbaum, Julia K. (Auteur) , Schneider, Gundolf (Auteur) , Schaub, Valdete (Auteur) , Hänel, Mathias (Auteur) , Hellmuth, Johannes C. (Auteur) , Dierlamm, Judith (Auteur) , Martin, Sonja (Auteur) , Mathas, Stephan (Auteur) , Meißner, Julia (Auteur) , Pegtel, D. Michiel (Auteur) , Zijlstra, Josée M. (Auteur) , Ossowski, Anna (Auteur) , Becker, Kerstin (Auteur) , Hallek, Michael (Auteur) , von Tresckow, Bastian (Auteur) , Borchmann, Peter (Auteur)
Format: Article (Journal)
Langue:anglais
Publié: 7 May 2026
In: Blood
Year: 2026, Volume: 147, Numéro: 19, Pages: 2194-2202
ISSN:1528-0020
DOI:10.1182/blood.2025031089
Accès en ligne:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood.2025031089
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0006497126003599
Accéder au texte intégral
Notes sur l'auteur:Jan-Michel Heger, Julia Mattlener, Helen Kaul, Justin Ferdinandus, Jessica Schneider, Julia K. Schleifenbaum, Gundolf Schneider, Valdete Schaub, Mathias Hänel, Johannes C. Hellmuth, Judith Dierlamm, Sonja Martin, Stephan Mathas, Julia Meissner, D. Michiel Pegtel, Josée M. Zijlstra, Anna Ossowski, Kerstin Becker, Michael Hallek, Bastian von Tresckow, Peter Borchmann, and Sven Borchmann
Description
Résumé:Beyond cure, major goals in patients with Hodgkin lymphoma (HL) are tailoring treatment to a patient’s individual risk for relapse to reduce acute and late toxicities, identifying candidates for early incorporation of novel agents, and making treatment affordable on a global level. Minimal residual disease (MRD) assessment by circulating tumor DNA (ctDNA) sequencing emerged as a promising strategy to achieve these goals; however, previous studies differed in sampling time points, assay validation, and definitions for MRD negativity. Here, we applied LymphoVista, a validated ctDNA sequencing assay for genotyping and MRD monitoring in lymphoma, to samples obtained from the German Hodgkin Study Group (GHSG) HD21 trial after 2 cycles of treatment (MRD-2) using a case-cohort design. Patients with positive MRD-2 result were at higher risk for relapse, progression, or death compared with MRD-2-negative patients (4-year progression-free survival [PFS], 36.7% vs 82.2%; hazard ratio, 5.3; 95% confidence interval, 2.0-13.8; P = .0008). After inverse probability weighting accounting for the number of events in the full reference set, patients with positive and negative MRD-2 results had 4-year PFS rates of 72.2% vs 95.3%. Combining MRD-2 with positron emission tomography after 2 cycles of BrECADD/eBEACOPP (PET-2) can identify patients at very low and patients at very high risk of relapse, progression, or death. In summary, these results suggest that MRD-2 assessment by LymphoVista allows for early outcome prognostication in patients with HL and could be used as a tool to improve treatment guidance on its own or in conjunction with PET-2.
Description:Online verfügbar 11 February 2026, Version des Artikels 7 May 2026
Gesehen am 23.07.2026
Description matérielle:Online Resource
ISSN:1528-0020
DOI:10.1182/blood.2025031089

Documents similaires